Kang Mo Kim
YOU?
Author Swipe
View article: Supplementary Figure S6 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S6 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S6. Full-length immunoblots used in the main and supplementary figures. (A) Full-length immunoblots of HIF-1a, c-Myc, pAkt, Akt, pERK, ERK and b-actin for Figure 2B. The red box indicates the image used in the main figures. (B) RT-P…
View article: Supplementary Figure S5 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S5 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S5. Knockdown of HIF1A enhances the cytotoxic effect of lenvatinib in Hep3B cells under hypoxic conditions. (A) Cell viability measured by MTS assays in Hep3B cells transfected with HIF1A siRNA or control. (B) Cell viability assays …
View article: Supplementary Table S3 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S3 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S3. Best overall response of the patients who received lenvatinib as a first-line treatment.
View article: Supplementary Table S5 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S5 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S5. Univariate and Multivariable Cox regression analysis of progression-free survival in the subcohort of the patients who received lenvatinib as a first-line treatment.
View article: Supplementary Table S1 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S1 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S1. Best overall responses before and after PS matching
View article: Supplementary Figure S2 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S2 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S2. Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival in the subcohort of the patients who received lenvatinib as a first-line treatment.
View article: Supplementary Table S2 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S2 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S2. Baseline characteristics of the patients who received lenvatinib as a first-line treatment.
View article: Supplementary Table S4 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S4 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S4. Univariate and Multivariable Cox regression analysis of overall survival in the subcohort of the patients who received lenvatinib as a first-line treatment.
View article: Supplementary Figure S4 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S4 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S4. Lenvatinib-induced HIF-1α degradation in hypoxic condition in other cell lines with different HIF-1α expression. Western blot analysis of HIF-1α, c-myc, pAKT, AKT, pERK, ERK, and β-actin after treating (A) Hep3B cells, (B) HepG2…
View article: Supplementary Figure S1 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S1 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S1. Patient flow chart. A total of 250 patients with advanced HCC (BCLC C) treated with lenvatinib were initially identified. After excluding 51 patients, 199 patients were eligible for analysis. After 1:1 propensity score matching,…
View article: Supplementary Figure S3 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S3 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S3. Lenvatinib-induced decreased cell viability in hypoxic condition is abrogated in other cell lines with relatively low HIF-1α expression. (A) Western blot analysis of HIF-1α and β-actin in Huh-7 cells and Hep3B cells in hypoxic c…
View article: Combined Transarterial Chemoembolization and External Beam Radiotherapy for Identifying Surgical Candidates for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score-Weighted Analysis
Combined Transarterial Chemoembolization and External Beam Radiotherapy for Identifying Surgical Candidates for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score-Weighted Analysis Open
Hepatic resection was significantly associated with improved OS in patients who showed objective responses after receiving combined TACE and RT for HCC with MVI.
View article: Supplementary Table S4 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S4 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S4. Univariate and Multivariable Cox regression analysis of overall survival in the subcohort of the patients who received lenvatinib as a first-line treatment.
View article: Supplementary Table S2 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S2 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S2. Baseline characteristics of the patients who received lenvatinib as a first-line treatment.
View article: Supplementary Figure S3 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S3 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S3. Lenvatinib-induced decreased cell viability in hypoxic condition is abrogated in other cell lines with relatively low HIF-1α expression. (A) Western blot analysis of HIF-1α and β-actin in Huh-7 cells and Hep3B cells in hypoxic c…
View article: Supplementary Table S3 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S3 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S3. Best overall response of the patients who received lenvatinib as a first-line treatment.
View article: Supplementary Figure S6 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S6 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S6. Full-length immunoblots used in the main and supplementary figures. (A) Full-length immunoblots of HIF-1a, c-Myc, pAkt, Akt, pERK, ERK and b-actin for Figure 2B. The red box indicates the image used in the main figures. (B) RT-P…
View article: Supplementary Figure S5 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S5 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S5. Knockdown of HIF1A enhances the cytotoxic effect of lenvatinib in Hep3B cells under hypoxic conditions. (A) Cell viability measured by MTS assays in Hep3B cells transfected with HIF1A siRNA or control. (B) Cell viability assays …
View article: Supplementary Figure S4 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S4 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S4. Lenvatinib-induced HIF-1α degradation in hypoxic condition in other cell lines with different HIF-1α expression. Western blot analysis of HIF-1α, c-myc, pAKT, AKT, pERK, ERK, and β-actin after treating (A) Hep3B cells, (B) HepG2…
View article: Supplementary Table S5 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S5 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S5. Univariate and Multivariable Cox regression analysis of progression-free survival in the subcohort of the patients who received lenvatinib as a first-line treatment.
View article: 15-Year Trends in Hepatocellular Carcinoma: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry
15-Year Trends in Hepatocellular Carcinoma: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry Open
Over the past 15 years, significant advancements in the early detection and treatment of HCC in Korea have led to improved survival outcomes. These findings underscore the need for ongoing clinical strategy evolution to address the changin…
View article: Supplementary Table S1 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Table S1 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Table S1. Best overall responses before and after PS matching
View article: Supplementary Figure S1 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S1 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S1. Patient flow chart. A total of 250 patients with advanced HCC (BCLC C) treated with lenvatinib were initially identified. After excluding 51 patients, 199 patients were eligible for analysis. After 1:1 propensity score matching,…
View article: Supplementary Figure S2 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Supplementary Figure S2 from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Figure S2. Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival in the subcohort of the patients who received lenvatinib as a first-line treatment.
View article: Data from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma
Data from Synergistic Effects of Transarterial Chemoembolization and Lenvatinib on HIF-1α Ubiquitination and Prognosis Improvement in Hepatocellular Carcinoma Open
Purpose:A recent trial has shown that adding transarterial chemoembolization (TACE) to lenvatinib therapy results in enhanced therapeutic efficacy in hepatocellular carcinoma (HCC). We aimed to assess the effectiveness of the lenvatinib an…
View article: Association Between Viral Replication Activity and Postoperative Recurrence of <scp>HBV</scp>‐Related Hepatocellular Carcinoma
Association Between Viral Replication Activity and Postoperative Recurrence of <span>HBV</span>‐Related Hepatocellular Carcinoma Open
Background Baseline viral replication activity influences the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B virus (HBV) infection. Aims To evaluate the impact of baseline viral replication activity…
View article: Synergistic effects of L-arginine and argininosuccinate synthetase 1 in inducing apoptosis in hepatocellular carcinoma
Synergistic effects of L-arginine and argininosuccinate synthetase 1 in inducing apoptosis in hepatocellular carcinoma Open
Backgrounds/Aims: Hepatocellular carcinoma (HCC) is a malignant cancer with an increasing incidence worldwide. Although numerous efforts have been made to identify effective therapies for HCC, current strategies have limitations. We presen…
View article: A Machine Learning Model to Predict De Novo Hepatocellular Carcinoma Beyond Year 5 of Antiviral Therapy in Patients With Chronic Hepatitis B
A Machine Learning Model to Predict De Novo Hepatocellular Carcinoma Beyond Year 5 of Antiviral Therapy in Patients With Chronic Hepatitis B Open
Background and Aims This study aims to develop and validate a machine learning (ML) model predicting hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients after the first 5 years of entecavir (ETV) or tenofovir (TFV) therapy…
View article: Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma
Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma Open
Introduction: Proteinuria presents a challenging complication during systemic therapy for hepatocellular carcinoma (HCC). This study aims to identify risk factors for proteinuria in patients with HCC treated with atezolizumab plus bevacizu…
View article: Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study
Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study Open
Aim: This post-marketing surveillance study evaluated the safety and effectiveness of lenvatinib as first-line treatment for unresectable hepatocellular carcinoma in Korea.Materials & methods: Adverse drug reactions (ADRs) an…